Quote:

---

Hi Leo — I will reach out soon. It would be good to update progress on the company’s pipeline, touch base on whether any update on seeking sanctions against Rosen, and, if you’re willing to talk about the uplisting to Nasdaq thing, I bet a lot of people probably have the same question I’ve had & asked you about last year but never specifically addressed in a story.

Don Seiffert
Life Sciences Editor
Boston Business Journal
617-316-3271
dseiffert@bizjournals.com

Sign up for the BBJ’s daily newsletters here: www.bizjournals.com/boston/promo/bbjemails

From: David...... @gmail.com>
Date: Friday, June 17, 2016 at 9:55 AM
To: 'Leo Ehrlich' <leo@cellceutix.com>
Cc: Don Seiffert <dseiffert@bizjournals.com>
Subject: RE: BOSTON Biz Journal ( Don Seiffert )

Thanks Gentlemen. And Leo, I am extremely proud to be a shareholder. Hope you both have a great week-end.

Regards,

David ( mobile xxxxxx )

From: Leo Ehrlich [mailto:leo@cellceutix.com]
Sent: Friday, June 17, 2016 9:50 AM
To: David
Cc: Don Seiffert
Subject: Re: BOSTON Biz Journal ( Don Seiffert )

Hi David,

Thank you for helping CTIX by being a proactive shareholder. After all, as a shareholder, it is your company.

Hi Don,

As you know I am always available to answer any questions you may have. David is correct that we were about to uplist. Even today my application is active with NASDAQ as I paid them an extension fee. My biggest regret was announcing the pending NASDAQ uplisting which in my opinion attracted shorting, hoping we will do a reverse stock split.

Best wishes,
Leo Ehrlich | CEO |
cellceutix
100 Cummings Center, Suite 151-B, Beverly, MA 01915
Leo@cellceutix.com

---